Journal of Pharmacology, Genetics and Molecular Biology (JPGMB)
ISSN: Applied | Vol. 01 Issue 01, February 2025 | pp. 102-118

Dopamine and Its Function in The Development of Depressive Disorders

Lukeshwari Sahu[1*], Apurva Yadav[2], Abha Rani[3]

[1]Raipur Institute of Pharmacy, Raipur, Chhattisgarh, India

[2]KIPS, Shri Shankaracharya Professional University, Bhilai, Chhattisgarh, India

[3]Raigarh College of Pharmacy, Raigarh, Chhattisgarh, India

*Corresponding Author E-mail: minisahujune1998@gmail.com

Abstract:

Dopamine is a very important neurotransmitter that has been studied for many physiological and psychological processes, including mood regulation. This review examines the role of dopamine in the etiology of depressive disorders. It will cover the literature available on this subject and analyze existing research in the field. Some of the most important findings emphasize the link between dopamine dysregulation and symptoms of depression, focusing on its role in reward processing, motivation, and cognitive functions. In review, the pathway of dopamine introduces methodological progresses in the study of dopamine pathways. This study discusses therapeutic implications, including dopamine-targeting treatments, and despite such great progress, understanding of precise mechanisms remains incomplete.

Keywords: Dopamine, Parkinson's, Alzheimer’s, Depression, GABA

1. INTRODUCTION

Dopamine is one of the central neurotransmitters for the reward system of the brain and has crucial functions in modulating mood, motivation, cognition, and behavior. It is among the primary monoamines responsible for neural communication in the pathway linked with pleasure, reward, and reinforcement learning [1]. It has been found to be the main dysfunction contributing to a plethora of psychiatric disorders, with depression being the main cause of disability in many people around the globe. Dopamine signaling and its association with depressive disorders have recently gained much importance as a field of research in the neuropsychiatry department. It sheds light on some potential mechanisms for depression pathophysiology.

Depressive disorders, also known as depression, are said to be characterized by persistent sadness and loss of interest or pleasure [2]. Cognitive impairments and disrupted sleep or appetite patterns are very common. Although its causes are somewhat multifactorial, ranging from genetic predispositions to environmental factors, neurochemical imbalances of the brain

comprise a cornerstone for its etiology. Serotonin and norepinephrine became the focus historically. However, newly emerging evidence stresses the crucial importance of dopamine especially in anhedonia the inability to enjoy pleasure a symptom core of depression.

The dopaminergic system consists of several pathways among them mesolimbic, mesocortical, and nigrostriatal tracts. Of these, the mesolimbic pathway is most significant in directing connectivity from the ventral tegmental area to nucleus accumbens and is vital in regulating reward and pleasure in rodents [3]. Altered activity in this pathway has been linked with reduced motivation and impaired hedonic capacity in individuals with depressive disorders. Besides that, another mesocortical pathway of VTA in connecting the prefrontal cortex participates in such cognitive processes like decision-making and attention. Therefore, abnormality of dopamine release and action may underlie cognitive deficits during depression.

Research suggests that major depressive disorders occur in conjunction with both hypo- and hyperdopaminergic states, not only dependent upon the region, but also upon the stage of a disorder. A good example: hypoactivity within mesolimbic dopamine pathways has been correlated with feelings of anhedonia and motivation deficits, while some other areas hyperactivity -like the amygdala- could strengthen negative affect as well as the reactivity toward stress. More than that, chronic stress, a known precipitant of depression, can further dysregulate dopamine synthesis, release, and receptor sensitivity, contributing to depressive symptoms. The interaction between stress hormones, such as cortisol, and dopamine signaling provides a mechanistic explanation for stress-induced depression.

Recent advances in neuroimaging, genetic studies, and animal models have elucidated the molecular mechanisms through which dopamine contributes to depressive disorders. Altered activity of dopamine transporters (DAT), dopamine receptor density, particularly D1 and D2 receptors, and enzymes involved in dopamine synthesis, like tyrosine hydroxylase, have been found in patients with depression. Genetic polymorphisms in genes coding for the dopaminergic system, such as the catechol-O-methyltransferase (COMT) gene, have been associated with susceptibility to depression.

Despite these insights, the role of dopamine in depressive disorders remains controversial. It is clear that dopamine's functions are far more complex than the simplistic "pleasure chemical" paradigm [4]. Its involvement in depression is complex, with overlapping contributions from other neurotransmitters and neural circuits. Understanding these complexities is critical for developing targeted treatments. Although the present antidepressant treatments, including SSRIs, mainly act on serotonergic neurotransmission, alternative approaches that are dopaminergic are currently under consideration. For example, drugs that upregulate the transmission of dopamine are thought to improve refractory depression, and examples include the drugs that are agonists at a dopamine receptor or atypical antipsychotics.

Dopamine's Function in Mood Regulation and Reward Processing

Dopamine is a critical transmitter in the brain's reward system. It is specifically involved in mood regulation, pleasure, and motivation. The release of dopamine would be essential in reward processing and reinforcement learning. Its malfunction has been strongly associated with symptoms such as anhedonia-an inability to experience pleasure, which is often a main characteristic of depressive disorders [5]. Often associated with decreased dopamine activity in the mesolimbic pathway, the pathway connecting the ventral tegmental area to the nucleus accumbens, and diminished motivation with reduced capacity for reward-driven behavior among depressed patients.

Cognitive Impairments and Dopamine Dysregulation

In addition to modulating mood and motivation, dopamine also affects attention, decision making, and memory [6]. In depressive disorders, abnormalities in dopamine signaling within the mesocortical pathway, which includes the projection of the VTA to the prefrontal cortex, contribute to cognitive impairment. Such alterations lead to distractibility, faulty decision making, and reduced cognitive flexibility, all hallmark features of the depressed state [7].

1.1.Objectives of the Study

- To condense the existing knowledge on the role of dopamine in depressive disorders.
- To critically review methods used and findings from current literature
- To discuss therapeutic implications of dopamine modulation in the treatment of depression.
- To identify gaps in the literatures and recommend further research directions.

1.2.Importance of the Topic

- **Global Prevalence of Depression:** With depression prevailing in millions globally, a great understanding about neurobiological findings is an indispensable requirement.
- **Targeted Therapies:** More about dopamine functions would reveal more advanced interventions.
- **Progress of Science:** The dopamine work contributes towards neurobiological and psychiatrical science overall.
- **Personalized Medicine:** Researching about genetics and neurochemistry helps make more personalized approaches with interventions in particular patients.

2. DOPAMINE DYSREGULATION IN DEPRESSION: MOOD, MOTIVATION, AND COGNITION

Dopamine dysregulation is a characteristic of depressive disorders, influencing mood, motivation, and cognitive functions [8]. There is evidence that reduced dopamine activity in the mesolimbic pathway contributes to anhedonia, a characteristic feature of depression. This loss of pleasure relates to

more pervasive disturbances in mood regulation. Moreover, dopamine signaling deficits impair reward processing and motivation in both human and animal studies. For example, low dopamine concentration in the nucleus accumbens inhibits seeking rewarding stimuli; this leads to apathy and a lack of goal-directed activity [9]. Cognitive impairment, including impairments in decision-making and executive functions, has been linked to disturbances in dopamine release in the prefrontal cortex. These observations underscore the role of dopamine as multifaceted in depression and suggest that interventions targeting these abnormalities will improve therapeutic outcomes [10].

Table 1: Research Study

References	Title	Topic Covered	Research Study
Nutt, D. J., Baldwin, D. S., & Clayton, A. H. (2006) [11]	The role of dopamine and norepinephrine in depression and antidepressant treatment	Role of dopamine and norepinephrine in depression	Investigated the interaction of dopamine and norepinephrine in depressive disorders to provide insight into their roles in mood regulation and how the therapeutic impacts of those antidepressants that target these neurotransmitters in depressive patients come into play.
Rampello, L., Nicoletti, F., & Nicoletti, F. (2000) [12]	Dopamine and depression: Therapeutic implications	Therapeutic implications of dopamine in depression	Explored the dopaminergic dysregulation which is linked to depression and discussed the potential therapeutic gains of targeting dopamine systems in depressive disorders
Nikolaus, S., Mamlins, E., Hautzel, H., & Müller, H. W. (2019) [13]	Acute anxiety disorder, major depressive disorder, bipolar disorder and schizophrenia are related to different patterns of nigrostriatal and mesolimbic dopamine dysfunction	Patterns of dopamine dysfunction in psychiatric disorders	Analyzed differences in nigrostriatal and mesolimbic dopamine dysfunction between different psychiatric disorders, including major depressive disorder, and highlighted patterns specific to depression

Podea, D., Suciu, R., Suciu, A. C., & Marinescu, I. (2009) [14]	The Role of Dopamine in Depression	Role of dopamine in depressive disorders	Contributed to the discussion about how dopamine dysregulation could be part of the pathology responsible for symptoms like anhedonia and motivational impairments and, hence, contribute to understanding the neurobiology of depression.
Yadid, G., & Friedman, A. (2008) [15]	Dynamics of the dopaminergic system as a key component to the understanding of depression	Dopaminergic system dynamics in depression	Discussed the dynamic changes in the dopaminergic system associated with depression, and reinforced the concept of it being involved in mood regulation and thus being a potential target for therapeutic intervention.
Delva, N. C., & Stanwood, G. D. (2021) [16]	Dysregulation of brain dopamine systems in major depressive disorder	Dopamine system dysregulation in MDD	Investigated the dysfunction of brain dopamine systems in major depressive disorder, by applying neuroimaging studies to reveal altered receptor activity and its relation to symptoms of depression.
Taylor, W. D., et al. (2022) [17]	Influences of dopaminergic system dysfunction on late-life depression	Dopaminergic dysfunction in late-life depression	Investigated the role of dopamine system dysfunction in late-life depression, emphasizing its effects on mood, motivation, and cognitive decline, and discussed the treatment implications for older populations

2.1.Dopamine and Mood Regulation

Dopamine plays a central role in mood regulation, and the involvement of this neurotransmitter in depressive disorders has

been widely reported in the scientific literature. One of the critical brain circuits implicated in mood regulation is the mesolimbic pathway, which plays a critical role in reward processing [18]. Studies have continually demonstrated that diminished dopamine levels within this pathway correlate with anhedonia, which is a fundamental symptom of depression: the loss of pleasure response to activities previously enjoyed. The neurobiological mechanism explains why depressed patients commonly have a reduced capacity to experience happiness or excitement [19]. Advances in neuroimaging techniques, particularly positron emission tomography, have provided more evidence of such dysregulation, as this is demonstrated through the alteration in dopamine receptor binding and decreased dopamine receptor availability within specific areas of the brain. Specifically, changes in these variables occur in the ventral striatum and nucleus accumbens, components that are a significant part of the brain's reward system [20]. These findings underscore the critical role that dopamine plays in mood regulation and underpin the significance of its impairment in the pathophysiology of depression.



Figure 1: Role Played by Serotonin and Dopamine in Mood & Feelings

2.2.Reward Processing and Motivation

Dopamine also plays an essential role in the reward system and motivation—both functions, more often than not, are derailed in the minds of those who are depressed [21]. Indeed, pathways involved with the dopaminergic system and nucleus accumbens as well as prefrontal cortex participate centrally in reward processing and motivational operations within the brain. Depressive disorders are often characterized by a lack of motivation and an inability to pursue and experience rewards, which are core aspects of the condition's symptomatology [22]. Studies of animal models of depression have proven helpful in identifying the role dopamine plays in reward processing, as evidence suggests that dopamine depletion in the nucleus accumbens results in impaired reward-seeking behavior and a general diminished capacity to engage in pleasurable activities. Functional MRI (fMRI) studies in humans confirm these

results. Activation within the striatum and prefrontal cortex regions during episodes of depression has been observed to be low. Such diminished activity could provide insight into dopamine system impairment, suggesting this neurotransmitter has an involvement with depression in motivation and underpinning its overall etiology as discussed below [23].

2.3.Cognitive Impairments and Dopamine

Cognitive impairments, including difficulties with decision-making, concentration, and executive function, are common features of depression and have been closely linked to disruptions in dopamine signaling, particularly in the prefrontal cortex. The prefrontal cortex, which is essential for higher-order cognitive functions such as planning, attention, and self-control, relies on dopamine for optimal performance [24]. Dysregulation in dopamine transmission within this region can lead to the cognitive deficits that are often observed in individuals with depression. Experimental studies using dopamine agonists, which aim to increase dopamine activity, have shown potential cognitive improvements in depressed patients, suggesting that enhancing dopaminergic function can mitigate some of the cognitive impairments associated with the disorder [25]. These findings highlight the therapeutic relevance of targeting dopamine pathways not only for improving mood and motivation but also for addressing the cognitive symptoms of depression, which can significantly impact a person's daily functioning and quality of life [26].



Figure 2: Understanding Mild Cognitive Impairment

3. METHODOLOGIES IN DOPAMINE RESEARCH

- **Neuroimaging:** Advanced imaging techniques now include positron emission tomography (PET) and functional magnetic resonance imaging (fMRI), which have revolutionized our perception of the

role of dopamine in depression. PET imaging allows for the imaging of dopamine receptor availability and activity in different regions of the brain, whereas fMRI outlines changes in brain activity that are associated with dopamine pathways. These methods show immediate evidence of dopamine's role in mood regulation and reward processing, although the expense and difficulty of these methods may limit their general application.

- **Pharmacological Studies:** Dopamine-targeting drugs have been very useful in attempting to better understand the role that this neurotransmitter plays in depression. For instance, dopaminergic enhancing drugs such as bupropion have been effective in treating depression and anhedonia. The dopamine agonist trials have also drawn attention to their potential use in providing a solution to motivational and cognitive deficits in depression. However, variation in individual response and side effects pose a problem for their universal application.
- **Genetic Studies:** Dopamine-related genes have also been associated with susceptibility to depressive disorders. A series of genetic studies have highlighted associations between altered dopamine signaling through DRD2, which codes for the D2 dopamine receptor, and alterations in dopamine metabolism by COMT and increased vulnerability to depression. This suggests a significant role of genetics in helping in the implementation of personalized approaches in treatment but at the same time shows that complexity of gene-environment interactions would be better understood.

Table 1: Summary of Dopamine-Targeting Therapies in Depression

Therapy	Mechanism of Action	Target Symptoms	Effectiveness and Limitations
Dopamine Reuptake Inhibitors	Increases synaptic dopamine levels	Anhedonia, apathy	Effective for motivation deficits; side effects include insomnia
Dopamine Agonists	Mimics dopamine activity	Cognitive impairment, anhedonia	Improves cognitive functions; response variability among patients
Combined Monoamine Therapy	Targets dopamine, serotonin, and norepinephrine	Broader symptom relief	Complex dosing; risk of interactions

3.1.Strengths and Weaknesses of Current Research

The series of research on dopamine and depression has made considerable progress in understanding the neurotransmitter's involvement in mood disorders [27]. With advanced neuroimaging techniques, there is substantial, visually demonstrable proof of dopamine's association, while pharmacological and genetic studies offer practical applicability toward therapeutic strategy [28].

Nonetheless, limitations exist. Many studies possess relatively small sample sizes, limiting the generalizability of their results. The inconsistency in methodologies-the imaging protocols varied among studies and also the diagnostic criteria for depression-added complexity to interstudy comparisons [29]. Moreover, a vast majority of these studies have been cross-sectional; thus, conclusions regarding causal effects of dopamine dysregulation to depression cannot be easily drawn [30]. The heterogeneity of depressive disorders makes research even more complicated, because variations in symptomatology may correspond to different underlying neurochemical mechanisms. Longitudinal studies and standardized methodologies are necessary to address these gaps and refine our understanding of dopamine's role in depression [31].

4. DISCUSSION

4.1.Interpret and Analyze the Findings

The findings in contemporary research establish firm evidence regarding the central position of dopamine in depressive disorder pathophysiology [32]. Indeed, decreased dopamine activity has been implicated and associated, repeatedly, with hallmark features of depression - notably anhedonia, as reflected by loss of pleasure in things once appreciated or enjoyed; reduced motivation; and impairment in various aspects of cognitive functions. Anhedonia, in particular, is likely due to a hypoactive reward system due to decreased dopamine signalling within regions such as the nucleus accumbens [33]. The decreased processing of rewards not only reduces the subject's ability to feel pleasure but also leads to decreased motivation and an overall decrease in engagement in goal-directed activities-a hallmark feature of depression.

Neuroimaging research has provided particularly strong evidence in support of these findings, demonstrating aberrant dopamine receptor availability and function in brain areas implicated in depression. For instance, reduced D2 receptor binding within the striatum has been documented in MDD patients, showing a correlation between receptor binding reductions and anhedonia and motivational impairments severity [34]. Reduced dopamine release in the prefrontal cortex, a brain region essential for cognitive processes such as decision-making, attention, and emotional regulation, has been demonstrated in functional imaging studies. This would suggest that dopaminergic dysfunction impacts not only mood and reward processing but also the cognitive impairments seen in depression [35].

Pharmacological treatments focused on dopamine reiterate its role in depressive disorders. Dopamine reuptake inhibitors, such as bupropion, and dopamine agonists, like pramipexole, have proven useful in the treatment of depression in patients who fail to respond to conventional SSRIs, serotonin-focused antidepressants [36]. These drugs are effective because they increase dopamine levels or stimulate dopamine receptors, countering the deficiencies in motivation and pleasure caused by the disorder. It clearly suggests the potential therapeutic approach that might target the dopamine pathway, particularly in improving the depression symptomatology less responsive to the usual treatment strategies.

In addition, the results demonstrate the complex and multifaceted function of dopamine within depression, spanning mood regulation as well as rewards and cognitive components. This integration represents the interconnected, holistic nature of the dopaminergic system with other neurotransmitters- serotonin and glutamate- and it is also correlated with stress and its mechanisms represented by the hypothalamic-pituitary-adrenal (HPA) axis [37]. Together, these networks may enhance dopaminergic derangement, expanding the range of observable depressive symptoms.

Table 2: Key Neurotransmitter Interactions in Depressive Disorders

Neurotransmitter	Role in Depression	Interaction with Dopamine	Implications for Research
Serotonin	Regulates mood and emotional stability	Dopamine and serotonin pathways interact to regulate mood	Co-treatment strategies for combined effects
Glutamate	Excitatory neurotransmitter involved in cognition	Modulates dopamine release in the prefrontal cortex	Requires exploration for combined therapies
Norepinephrine	Influences arousal and stress response	Works synergistically with dopamine in reward circuits	Potential for dual-pathway interventions

4.2.Discuss Implications and Significance

The implications of dopamine's role in depressive disorders go deep, as they influence the direction of clinical practice and future research. Clinically, this understanding has led to the development of targeted therapies - dopamine agonists, dopamine reuptake inhibitors, and atypical

antipsychotics-in an attempt to address dopaminergic dysfunction directly [38]. These alternative treatments are reserved for patients who do not adequately respond to a number of conventional antidepressants, including SSRIs or SNRIs. They try to directly target the dopamine pathways to treat core depression symptoms, such as anhedonia and motivational deficits, which conventional therapies often fail to address properly. For example, drugs like bupropion, which is a norepinephrine-dopamine reuptake inhibitor, are effective in treating depression, which improves energy and reduces apathy, thereby supporting the clinical importance of the dopaminergic system.

From a research point of view, genetic studies of dopamine-related genes, such as those encoding dopamine receptors (D1, D2) and transporters (DAT), opened new avenues in the direction of personalized medicine. Such knowledge enables the identification of individuals with a genetic predisposition to dopaminergic dysregulation, and therefore opens a way for individually tailored interventions [39]. For example, patients with some polymorphisms in the COMT or DAT gene may be better responders to therapies affecting dopamine pathways. This precision medicine could significantly increase efficacy in treatments with reduced prescription failure, eventually boosting patient outcome improvements.

Finally, knowing how dopamine works in depression also helps better appreciate the wider pathology of depression. This reminds one to use an integrative model of considering how dopaminergic, serotonergic, and other neurotransmitter systems interrelate. Interactions of dopamine with mechanisms related to stress, including the HPA axis, its participation in reward processing, cognition, and emotion, further drive the concept of central importance to depression's complex pathology [40]. This will, therefore, be important in the development of integrated treatment strategies targeted at diverse symptoms and their underlying neurobiological mechanisms to help manage depression. This progress will not only fine-tune therapeutic options but also help alleviate the stigma of depression by depicting it not as just a psychological condition but a complex neurobiological one.

4.3.Gaps and Suggest Future Research Directions

Gaps in Current Research

1. **Methodological Inconsistencies**: Methodological inconsistencies across the studies are major challenges in the understanding of the role of dopamine in depression. Inconsistencies in imaging protocols are also seen because of the heterogeneity in using PET and fMRI techniques across different studies, which makes comparison difficult and hence leads to indefinite conclusions. Further, sample heterogeneity in terms of age, gender, and other comorbid conditions reduces the reliability of results and limits its applicability across diverse populations. These issues point out the need for more standardized approaches in research design.

2. **Cross-Sectional Study Designs**: The majority of the current work depends upon cross-sectional designs, which can give only a snapshot of dopamine activity at any particular time. Although such studies have been truly helpful in establishing associations with depressive symptoms via dopamine dysregulation, they have failed to prove any causal associations. Without longitudinal data, no one has known whether dopamine dysfunction is the cause or the result of depression. It points, therefore, to the need for stronger temporal analysis.
3. **Limited Exploration of Neurotransmitter Interactions**: Most studies focus solely on dopamine without considering interactions that might exist between it and other key neurotransmitters such as serotonin, norepinephrine, and glutamate. Such a confined approach leads to an incomplete understanding of the neurobiology involved in depression. Since depression is a disease of many neural systems, looking into interactions between these neurotransmitters might offer a more holistic perspective and a better view of the mechanisms involved.
4. **Lack of Diverse Populations**: Studies involving dopamine and depression are usually done in narrow demographics, with specific age ranges or cultural settings. This makes findings less generalizable and might ignore population-specific differences in dopamine function. More diverse samples are therefore needed to ensure the generalizability of findings across the global population.
5. **Standardization Challenges**: The lack of standardized methodologies in experimental designs, diagnostic criteria, and outcome measures poses a great challenge to the synthesis of findings. The lack of standardization in the measurement of depression and dopamine dysregulation across studies complicates the translation of research insights into clinical practice. To address this, there is a need for a consensus on standard protocols and diagnostic tools.

Suggestions for Future Research Directions

1. **Longitudinal Study Designs**: Future research endeavors should utilize more longitudinal study designs to identify better the time dependency of the dynamics involved with dopamine in depressive disorders. Researchers can use observations of alterations occurring over time, thereby increasing one's knowledge to understand if depression is either predisposed or represents a development effect of this particular disorder.
2. **Integrated Neurotransmitter Models**: There is a necessity to study further the interaction between dopamine and the other neurotransmitter systems, serotonin,

norepinephrine, and glutamate. In this way, the neurochemical networks involved in depression can be understood more clearly, which should lead to effective multimodal treatments.

3. **Standardized Methodologies**: Improved standardization of research approaches, in that imaging protocols and diagnostic criteria can be more uniformly applied with greater consistency between the studies so as to enable improved meta-analysis reliability of the findings regarding the contribution of dopamine in depression.

4. **Inclusion of Diverse Populations**: Future research will require inclusion of participants across the spectrum of diverse age groups, ethnicities, and socio-economic backgrounds. Such diversity is essential for recognizing population-specific differences in dopamine function and making findings as generalizable as possible so that the results apply broadly to most populations.

5. **Exploration of Environmental and Genetic Interactions**: Future studies should investigate how such environmental factors as stress or trauma, and dopamine-related genetic variations, interact on each other in determining the overall risk of depression- related susceptibility. It can be useful in elucidating individual susceptibility and paving the way for more personalized interventions.

6. **Development of Biomarkers**: Biomarkers should be developed and identified, related to dopamine that could be useful in diagnosing depression, in monitoring responses to treatment, and in predicting clinical outcomes. This would make depression management much more accurate and effective.

7. **Intervention Studies**: Finally, clinical research is necessary with regard to how novel therapies focused on the stimulation of dopaminergic transmission have efficacy; particularly, such therapy includes pharmacological agents as dopamine agonists and reuptake inhibitors. These investigations would also be about how long it remains safe and effective in practice and especially among treatment-resistant patients.

5. CONCLUSION

This review puts in perspective dopamine's critical role in the etiology of depressive disorders, specifically how it is associated with mood regulation, reward processing, and cognitive functions. Central depressive symptoms like anhedonia and poor motivation are very well related to dysfunction in the dopaminergic pathway, emphasizing the importance of the dopaminergic system in the pathophysiology of the disorder. This understanding, therefore, would not only benefit scientific research but also depression as a significant public health challenge. Insights from this research could therefore revolutionize the clinical practices and inform the creation of more specific and

effective treatments. However, to further maximize such discoveries, additional future research ought to be targeted at filling in areas using a longitudinal approach, interaction with other neurochemical systems of dopamine, and the establishment of a standardized method to deal with variability amongst studies. In addition, diverse population samples will continue to enhance generalizability and advocate for establishing personalized therapy that would enhance treatment outcomes amongst depressed individuals.

REFERENCES

1. Belujon, P., & Grace, A. A. (2017). Dopamine system dysregulation in major depressive disorders. International Journal of Neuropsychopharmacology, 20(12), 1036-1046.
2. Dunlop, B. W., & Nemeroff, C. B. (2007). The role of dopamine in the pathophysiology of depression. Archives of general psychiatry, 64(3), 327-337.
3. Malhi, G. S., & Berk, M. (2007). Does dopamine dysfunction drive depression?. Acta Psychiatrica Scandinavica, 115, 116-124.
4. Ayano, G. J. J. M. D. T. (2016). Dopamine: receptors, functions, synthesis, pathways, locations and mental disorders: review of literatures. J Ment Disord Treat, 2(120), 2.
5. Opmeer, E. M., Kortekaas, R., & Aleman, A. (2010). Depression and the role of genes involved in dopamine metabolism and signalling. Progress in neurobiology, 92(2), 112-133.
6. Money, K. M., & Stanwood, G. D. (2013). Developmental origins of brain disorders: roles for dopamine. Frontiers in cellular neuroscience, 7, 260.
7. Montgomery, S. A. (2008). The under-recognized role of dopamine in the treatment of major depressive disorder. International Clinical Psychopharmacology, 23(2), 63-69.
8. Leggio, G. M., Salomone, S., Bucolo, C., Platania, C., Micale, V., Caraci, F., & Drago, F. (2013). Dopamine D3 receptor as a new pharmacological target for the treatment of depression. European journal of pharmacology, 719(1-3), 25-33.
9. Felger, J. C. (2017). The role of dopamine in inflammation-associated depression: mechanisms and therapeutic implications. Inflammation-Associated Depression: Evidence, Mechanisms and Implications, 199-219.
10. Cousins, D. A., Butts, K., & Young, A. H. (2009). The role of dopamine in bipolar disorder. Bipolar disorders, 11(8), 787-806.
11. Nutt, D. J., Baldwin, D. S., & Clayton, A. H. (2006). The role of dopamine and norepinephrine in depression and antidepressant treatment. Journal of Clinical Psychiatry, 67(Suppl 6), 3-8.
12. Rampello, L., Nicoletti, F., & Nicoletti, F. (2000). Dopamine and

depression: Therapeutic implications. CNS drugs, 13, 35-45.
13. Nikolaus, S., Mamlins, E., Hautzel, H., & Müller, H. W. (2019). Acute anxiety disorder, major depressive disorder, bipolar disorder and schizophrenia are related to different patterns of nigrostriatal and mesolimbic dopamine dysfunction. Reviews in the Neurosciences, 30(4), 381-426.
14. Podea, D., Suciu, R., Suciu, A. C., & Marinescu, I. (2009). The Role of Dopamine in Depression. Rom. J. Psycopharmacol, 9, 145-153.
15. Yadid, G., & Friedman, A. (2008). Dynamics of the dopaminergic system as a key component to the understanding of depression. Progress in brain research, 172, 265-286.
16. Delva, N. C., & Stanwood, G. D. (2021). Dysregulation of brain dopamine systems in major depressive disorder. Experimental Biology and Medicine, 246(9), 1084-1093.
17. Taylor, W. D., Zald, D. H., Felger, J. C., Christman, S., Claassen, D. O., Horga, G., ... & Rutherford, B. R. (2022). Influences of dopaminergic system dysfunction on late-life depression. Molecular psychiatry, 27(1), 180-191.
18. Kikuchi, T., Maeda, K., Suzuki, M., Hirose, T., Futamura, T., & McQuade, R. D. (2021). Discovery research and development history of the dopamine D2 receptor partial agonists, aripiprazole and brexpiprazole. Neuropsychopharmacology Reports, 41(2), 134-143.
19. Latif, S., Jahangeer, M., Razia, D. M., Ashiq, M., Ghaffar, A., Akram, M., ... & Ansari, M. A. (2021). Dopamine in Parkinson's disease. Clinica chimica acta, 522, 114-126.
20. Jiang, Y., Zou, D., Li, Y., Gu, S., Dong, J., Ma, X., ... & Huang, J. H. (2022). Monoamine neurotransmitters control basic emotions and affect major depressive disorders. Pharmaceuticals, 15(10), 1203.
21. Kanarik, M., Grimm, O., Mota, N. R., Reif, A., & Harro, J. (2022). ADHD co-morbidities: A review of implication of gene× environment effects with dopamine-related genes. Neuroscience & Biobehavioral Reviews, 139, 104757.
22. Williams, O. O., Coppolino, M., George, S. R., & Perreault, M. L. (2021). Sex differences in dopamine receptors and relevance to neuropsychiatric disorders. Brain sciences, 11(9), 1199.
23. Hamidianjahromi, A., & Tritos, N. A. (2022). Impulse control disorders in hyperprolactinemic patients on dopamine agonist therapy. Reviews in Endocrine and Metabolic Disorders, 23(5), 1089-1099.
24. Ramesh, S., & Arachchige, A. S. P. M. (2023). Depletion of dopamine in Parkinson's disease and relevant therapeutic options: A review of the literature. AIMS neuroscience, 10(3), 200.

25. Correia, A. S., Cardoso, A., & Vale, N. (2021). Highlighting immune system and stress in major depressive disorder, Parkinson's, and Alzheimer's diseases, with a connection with serotonin. International Journal of Molecular Sciences, 22(16), 8525.
26. Duval, F., Mokrani, M. C., Erb, A., Danila, V., Lopera, F. G., Foucher, J. R., & Jeanjean, L. C. (2021). Thyroid axis activity and dopamine function in depression. Psychoneuroendocrinology, 128, 105219.
27. Bekhbat, M., Li, Z., Mehta, N. D., Treadway, M. T., Lucido, M. J., Woolwine, B. J., ... & Felger, J. C. (2022). Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Molecular Psychiatry, 27(10), 4113-4121.
28. Ahmad, M. H., Rizvi, M. A., Ali, M., & Mondal, A. C. (2023). Neurobiology of depression in Parkinson's disease: Insights into epidemiology, molecular mechanisms and treatment strategies. Ageing research reviews, 85, 101840.
29. Grunze, H., Csehi, R., Born, C., & Barabássy, Á. (2021). Reducing addiction in bipolar disorder via hacking the dopaminergic system. Frontiers in Psychiatry, 12, 803208.
30. Chen, S., Gao, L., Li, X., & Ye, Y. (2021). Allopregnanolone in mood disorders: Mechanism and therapeutic development. Pharmacological Research, 169, 105682.
31. Kiss, B., Laszlovszky, I., Krámos, B., Visegrády, A., Bobok, A., Lévay, G., ... & Román, V. (2021). Neuronal dopamine D3 receptors: translational implications for preclinical research and CNS disorders. Biomolecules, 11(1), 104.
32. Mandal, P. K., Gaur, S., Roy, R. G., Samkaria, A., Ingole, R., & Goel, A. (2022). Schizophrenia, bipolar and major depressive disorders: overview of clinical features, neurotransmitter alterations, pharmacological interventions, and impact of oxidative stress in the disease process. ACS Chemical Neuroscience, 13(19), 2784-2802.
33. Ortega, M. A., Fraile-Martínez, Ó., García-Montero, C., Alvarez-Mon, M. A., Lahera, G., Monserrat, J., ... & Alvarez De Mon, M. (2022). Nutrition, epigenetics, and major depressive disorder: understanding the connection. Frontiers in Nutrition, 9, 867150.
34. Marx, W., Penninx, B. W., Solmi, M., Furukawa, T. A., Firth, J., Carvalho, A. F., & Berk, M. (2023). Major depressive disorder. Nature Reviews Disease Primers, 9(1), 44.
35. Dalvi-Garcia, F., Fonseca, L. L., Vasconcelos, A. T. R., Hedin-Pereira, C., & Voit, E. O. (2021). A model of dopamine and serotonin-kynurenine metabolism in cortisolemia: Implications for depression. PLoS

computational biology, 17(5), e1008956.
36. Franco, R., Reyes-Resina, I., & Navarro, G. (2021). Dopamine in health and disease: much more than a neurotransmitter. Biomedicines, 9(2), 109.
37. Silva, R. C., Maffioletti, E., Gennarelli, M., Baune, B. T., & Minelli, A. (2021). Biological correlates of early life stressful events in major depressive disorder. Psychoneuroendocrinology, 125, 105103.
38. Mandic-Maravic, V., Grujicic, R., Milutinovic, L., Munjiza-Jovanovic, A., & Pejovic-Milovancevic, M. (2022). Dopamine in autism spectrum disorders—focus on D2/D3 partial agonists and their possible use in treatment. Frontiers in psychiatry, 12, 787097.
39. Prange, S., Klinger, H., Laurencin, C., Danaila, T., & Thobois, S. (2022). Depression in patients with Parkinson's disease: current understanding of its neurobiology and implications for treatment. Drugs & Aging, 39(6), 417-439.
40. Kamran, M., Bibi, F., ur. Rehman, A., & Morris, D. W. (2022). Major depressive disorder: existing hypotheses about pathophysiological mechanisms and new genetic findings. Genes, 13(4), 646.